Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

N/A

3(60.0%)

Phase 4

1(20.0%)

Phase 3

1(20.0%)

5Total

N/A(3)

Phase 4(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03977493Phase 3Recruiting

IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia

Role: lead

NCT03968744Phase 4Terminated

Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease

Role: lead

NCT07097298Not ApplicableRecruiting

Empathy and (Self-)Compassion in Parkinson's Disease Patients and Caregivers

Role: lead

NCT06584084Not ApplicableRecruiting

Technical and Clinical Validation of the WPM-SEMG Prototype

Role: lead

NCT05849896Not ApplicableRecruiting

Clinical Relevance of the HD sEMG Signals in the Post-stroke Rehabilitation

Role: lead

All 5 trials loaded